Stingray Therapeutics Competitors and Similar CompaniesClear all

Stingray Therapeutics's competitors and similar companies include Merrimack Pharmaceuticals, CytomX Therapeutics and Nektar Therapeutics.

	Stingray Therapeutics Stingray Therapeutics is a company that specializes in immunotherapy to fight cancer.	Merrimack Pharmaceuticals Merrimack Pharmaceuticals discovers, designs and develops therapies for the treatment of diseases in the areas of autoimmunity and cancer.	CytomX Therapeutics CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of antibody therapeutics based on Probody technology platform.	Nektar Therapeutics Nektar Therapeutics is a stage-clinical biopharmaceutical company.
Founding Date	Founding Date 2018	Founding Date 2000	Founding Date 2008	Founding Date 1990
Type	Type Private	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma
Locations	Locations Houston, US HQ	Locations Cambridge, US HQ	Locations South San Francisco, US HQ	Locations San Francisco, US HQ Hyderabad, IN Huntsville, US
Employees	Employees 7	Employees 2763% decrease	Employees 15815% increase	Employees 61821% increase
Valuation ($)	Valuation ($) N/A	Valuation ($) 223.7 m	Valuation ($) 78 m	Valuation ($) 233.8 m
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) $76.2m (FY, 2025)	Revenue (est.) $55.2m (FY, 2025)
Net income	Net income N/A	Net income ($1.2m) (FY, 2023)	Net income ($17.4m) (FY, 2025)	Net income ($164.1m) (FY, 2025)
Funding
Total funding raised	Total funding raised N/A	Total funding raised $ 79.4m	Total funding raised $ 132.4m	Total funding raised $ 45m